
## Asadur Rahman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6784773/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. Frontiers in Endocrinology, 2018, 9, 421.	1.5	84
2	A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. PLoS ONE, 2018, 13, e0192531.	1.1	60
3	A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertension Research, 2016, 39, 415-422.	1.5	51
4	Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia, 2015, 58, 2885-2898.	2.9	49
5	Interactions between Host PPARs and Gut Microbiota in Health and Disease. International Journal of Molecular Sciences, 2019, 20, 387.	1.8	46
6	Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. Journal of Hypertension, 2016, 34, 893-906.	0.3	45
7	Effect of a selective <scp>SGLT</scp> 2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 522-525.	0.9	43
8	Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. Journal of Human Hypertension, 2021, 35, 148-156.	1.0	38
9	Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. Hypertension Research, 2017, 40, 535-540.	1.5	33
10	Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Pharmacological Effects of Mineralocorticoid-Receptor Blockers. Journal of Pharmacological Sciences, 2009, 109, 1-6.	1.1	31
11	High sodium augments angiotensin II-induced vascular smooth muscle cell proliferation through the ERK 1/2-dependent pathway. Hypertension Research, 2014, 37, 13-18.	1.5	28
12	Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertension Research, 2015, 38, 237-243.	1.5	28
13	Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease. Hypertension Research, 2020, 43, 492-499.	1.5	28
14	Responses of renal hemodynamics and tubular functions to acute sodium–glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. Scientific Reports, 2017, 7, 9555.	1.6	26
15	Altered Circadian Timing System-Mediated Non-Dipping Pattern of Blood Pressure and Associated Cardiovascular Disorders in Metabolic and Kidney Diseases. International Journal of Molecular Sciences, 2018, 19, 400.	1.8	26
16	Melatonin in chronic kidney disease: a promising chronotherapy targeting the intrarenal renin–angiotensin system. Hypertension Research, 2019, 42, 920-923.	1.5	22
17	Human pluripotent stem cell–derived erythropoietin-producing cells ameliorate renal anemia in mice. Science Translational Medicine, 2017, 9, .	5.8	19
18	Current Status of Exposed Endoscopic Full-Thickness Resection and Further Development of Non-Exposed Endoscopic Full-Thickness Resection. Digestion, 2017, 95, 6-15.	1.2	19

Asadur Rahman

#	Article	IF	CITATIONS
19	PPARγ activation mitigates glucocorticoid receptorâ€induced excessive lipolysis in adipocytes via homeostatic crosstalk. Journal of Cellular Biochemistry, 2018, 119, 4627-4635.	1.2	17
20	Renoprotective Effects of Mangiferin: Pharmacological Advances and Future Perspectives. International Journal of Environmental Research and Public Health, 2022, 19, 1864.	1.2	14
21	Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats. International Journal of Molecular Sciences, 2021, 22, 2069.	1.8	11
22	The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats. Journal of Pharmacological Sciences, 2020, 142, 124-126.	1.1	10
23	Antiproliferative Effects of Monoclonal Antibodies against (Pro)Renin Receptor in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2020, 19, 1844-1855.	1.9	10
24	IBMX protects human proximal tubular epithelial cells from hypoxic stress through suppressing hypoxia-inducible factor-11± expression. Experimental Cell Research, 2017, 358, 343-351.	1.2	7
25	Association of a Disrupted Dipping Pattern of Blood Pressure with Progression of Renal Injury during the Development of Salt-Dependent Hypertension in Rats. International Journal of Molecular Sciences, 2020, 21, 2248.	1.8	6
26	Innovative delivery method using a detachable device to deliver a large polyglycolic acid sheet to a gastric ulcer perforation. Endoscopy, 2017, 49, E165-E167.	1.0	5
27	Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H. Communications Biology, 2020, 3, 724.	2.0	5
28	Novel and effective countertraction using a ring-shaped thread for safer gastric and colorectal endoscopic submucosal dissection. Gastrointestinal Endoscopy, 2016, 84, 735-736.	0.5	4
29	The Development of Endoscopic Suturing Devices: Challenges in the Treatment of latrogenic Perforation and Bleeding. Internal Medicine, 2016, 55, 3075-3076.	0.3	2
30	Combination therapy of overâ€theâ€scopeâ€clip and covered metallic stent for refractory multiple esophagobronchial fistulae and stenosis. Digestive Endoscopy, 2017, 29, 393-394.	1.3	2
31	Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats. Journal of Pharmacological Sciences, 2021, 146, 98-104.	1.1	1
32	Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on accumulation of aliskiren in the kidney. Journal of Hypertension, 2013, 31, 659-660.	0.3	0
33	Antiproliferative effects of polyclonal antibody against (pro) renin receptor in pancreatic ductal adenocarcinoma cells. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-29.	0.0	0